The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Xiong, Xiaowei ^a   Liu, Hong ^a   Hua, Lu ^a   Zhao, Hui ^a   Wang, Dongxue ^b   Li, Yishi ^a  

^a FUWAI HOSPITAL   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apolipoprotein CIII (apoCIII); Coronary heart disease (CHD); High density lipoprotein (HDL); Statin

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; AGED; BLOOD; CORONARY DISEASE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; APOLIPOPROTEIN C-III; ATORVASTATIN CALCIUM; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PRAVASTATIN; ROSUVASTATIN CALCIUM; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84943338535     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0129-8     Document Type: Article

References (39)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95.
2. The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
3. Steinberg D. Hypercholesterolemia and inflammation in atherogenesis: Two sides of the same coin. Mol Nutr Food Res. 2005;49(11):995-8.
4. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorle PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoprotiens A-I and B, and HDL density subfractions: The atherosclerosis Risk in Communities (ARIC) study. Circulation. 2001;104(10):1108-13.
5. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
6. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304-16.
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22.
8. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoprotiens B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) Trial. Circulation. 2000;102(16):1886-92.
9. Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol. 2012;10(4):410-21.
10. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotien C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2012;121(15):1722-34.
11. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotien CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114(7):681-7.
12. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotien CIII in apoliprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113(5):691-700.
13. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotien C-III and the risk of coronary heart disease. Circulation. 2011;124(19):2065-72.
14. Scheffer PG, Teerlink T, Dekker JM, Bos G, Nijpels G, Diamant M, et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem. 2008;54(8):1325-30.
15. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary disease: role of high-density lipoprotein-proteome remodeling. Circulation. 2013;127(8):891-904.
16. Jensen MK, Rimm EB, Furtado JD, Sacks FM. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc. 2012;1(2):e000232. doi: 10.1161/JAHA.111.000232.
17. Chang PY, Lee CM, Hsu HC, Lin HJ, Chien KL, Chen CH, et al. Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan. Lipids Health Dis. 2012;11:162.
18. Blankenhorn DH, Alaupovic P, Wickam E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 1990;81(2):470-6.
19. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
20. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin, simvastatin, and pravastatin across doses (STELLAR∗Trial). Am J Cardiol. 2003;92(2):152-60.
21. Yan LR, Wang DX, Liu H, Zhang XX, Zhao H, Hua L, et al. A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labeling-based proteomic approach. PLoS One. 2014;9(5):e98368.
22. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114(10):611-24.
23. Malmendier CL, Lontie JF, Grutman GA, Delcroix C. Metabolism of apolipoprotein C-III in normolipemic human subjects. Atherosclerosis. 1988;69(1):51-9.
24. Tornoci L, Scheraldi CA, Li X, Ide H, Goldberg IJ, Le NA. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res. 1993;34(10):1793-803.
25. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013;38(4):754-68.
26. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, Jankowski J, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 2012;94(1):154-62.
27. Van Lenten BJ, Hama SY, de Bee FC, Stafforini DM, Mclntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96(6):2758-67.
28. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear facto-kappaB in endothelial cells. J Cardiovasc Pharmacol. 2007;49(6):376-83.
29. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
30. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 2000;49(2):167-77.
31. Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, et al. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis. 1999;146(2):369-79.
32. Zheng C, Azcutia V, Aikawa E, Fiqueiredo JL, Croce K, Sonoki H, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J. 2013;34(8):615-24.
33. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7):786-98.
34. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Aki EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ. 2009;338:b92.
35. Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27(6):1358-64.
36. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-44.
37. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23(5):853-8.
38. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-71.
39. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. Apolipoprotein c-III, a strong discrminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168(1):81-9.